NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $49.7273.

NAMS has been the subject of a number of recent analyst reports. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. HC Wainwright reaffirmed a “buy” rating and set a $52.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. Royal Bank Of Canada dropped their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $22.49 on Friday. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -10.41 and a beta of 0.09. NewAmsterdam Pharma has a fifty-two week low of $21.02 and a fifty-two week high of $42.21. The stock has a 50 day moving average of $27.20 and a 200 day moving average of $30.74.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. Analysts forecast that NewAmsterdam Pharma will post -1.82 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Kooij sold 105,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John W. Smither sold 1,600 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the sale, the director directly owned 8,760 shares in the company, valued at approximately $221,803.20. The trade was a 15.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 271,600 shares of company stock worth $7,797,962. Company insiders own 12.74% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of NAMS. Frazier Life Sciences Management L.P. increased its stake in NewAmsterdam Pharma by 6.8% during the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after purchasing an additional 1,145,128 shares during the period. Castle Hook Partners LP acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $38,062,000. Bank of America Corp DE lifted its holdings in NewAmsterdam Pharma by 84.4% during the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock worth $27,115,000 after buying an additional 387,698 shares in the last quarter. Artia Global Partners LP boosted its position in NewAmsterdam Pharma by 158.6% in the 4th quarter. Artia Global Partners LP now owns 503,936 shares of the company’s stock valued at $17,678,000 after buying an additional 309,098 shares during the period. Finally, Maverick Capital Ltd. boosted its position in NewAmsterdam Pharma by 15.4% in the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after buying an additional 292,176 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.